Showing results (271-280 of 289) with videos related to
Sort By:
Pageof 29
Journal of AOAC International|August 31, 2017
Detection of Paralytic Shellfish Toxins in Mussels and Oysters Using the Qualitative Neogen Lateral-Flow Immunoassay: An Interlaboratory StudyJuan José Dorantes-Aranda, Jessica Y C Tan, Gustaaf M Hallegraeff, et al.Biorxiv : the Preprint Server for Biology|November 28, 2023
COQ4 is required for the oxidative decarboxylation of the C1 carbon of Coenzyme Q in eukaryotic cellsLudovic Pelosi, Laura Morbiato, Arthur Burgardt, et al.JAMA Surgery|October 22, 2025
Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 StudyTina J Hieken, Michael E Egger, Christina V Angeles, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.Molecular Cell|January 31, 2024
COQ4 is required for the oxidative decarboxylation of the C1 carbon of coenzyme Q in eukaryotic cellsLudovic Pelosi, Laura Morbiato, Arthur Burgardt, et al.Mbio|February 10, 2011
Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hostsC A D'Souza, J W Kronstad, G Taylor, et al.Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.Journal of the American College of Surgeons|December 14, 2020
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisKristy K Broman, Tasha M Hughes, Lesly A Dossett, et al.Cancer|April 7, 2021
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, et al.Pageof 29